On the recordJuly 26, 2023
Mr. Chairman, I yield myself 1 minute. Mr. Chair, I rise in strong support of my amendment to H.R. 4366. This amendment will ensure the VA conducts large-scale studies into the efficacy of drugs with FDA breakthrough therapy status to treat post-traumatic stress disorder through medication-assisted therapy trials. {time} 1545 Every day, roughly 20 veterans take their own life. This number has stayed high despite our best efforts here in Washington. Fortunately, new breakthrough therapies have offered significant help. Under the Trump administration, the FDA granted breakthrough therapy status for MDMA-assisted therapy to treat PTSD. Since then, privately funded research has demonstrated clear, positive results in treating previously untreatable PTSD with little or no risk for patients. This includes studies in cooperation with the VA, for instance, at the Bronx VA hospital. Let me be clear. These trials are conducted with full FDA approval, under medical supervision, and in safe clinical environments. The Acting CHAIR. The time of the gentleman has expired.





